GB2434312A — Cannabinoid extracts for treating neurodegeneration
Assigned to GW Pharma Ltd · Expires 2007-07-25 · 19y expired
What this patent protects
The invention relates to the use of extracts of cannabis plants for treating neurological degeneration .such as alzheimer's, huntingdon's and parkinson's diseases, dementia, multiple sclerosis, Downs syndrome, prion disease, palsy, spinal cord injury or alcohol induced neurotoxic…
USPTO Abstract
The invention relates to the use of extracts of cannabis plants for treating neurological degeneration .such as alzheimer's, huntingdon's and parkinson's diseases, dementia, multiple sclerosis, Downs syndrome, prion disease, palsy, spinal cord injury or alcohol induced neurotoxicity. Preferably the extract contains a cannabinoid:non-cannabinoid fraction in a ratio of between 60:40 90:10. The cannabinoid fraction may contain tetrahydrocannabinol (THC), cannabidiol (CBD), tetrahydrocannabidivarin (THCV), cannabigerol (CBG), cannabichromeme (CBC) tetrahydrocannabinolic acid (THCA), cannabidivarin (CBDV) and cannadidiolic acid (CBDA).
Drugs covered by this patent
- Epidiolex (CANNABIDIOL) · Jazz Pharms Res
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.